4MO Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study
Titel:
4MO Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study
Auteur:
Yang, Y. Wang, Z. Fang, J. Yu, Q. Han, B. Cang, S. Chen, G. Mei, X. Yang, Z. Stefaniak, V. Lin, Y. Wang, S. Zhang, W. Sun, L. Zhang, Y.